The Southeastern Health AI Consortium (SEHAI) is a partnership with the Medical University of South Carolina and the University of Florida. It has helped launch $6.6 million in pilot awards designed to test how AI can move from a promising tool to a practical driver of better health outcomes across the Southeast.
Use this guidance and its sections to improve your UF biography.
Images tell stories, like this one showcasing a student participant at a HOBI event. The alt text reads: Student Zijian Xu points to a section of his scientific poster, as he explains his research to a HOBI education day poster showcase attendee. Well chosen and designed images and graphics make…
University of Florida health researchers are expanding collaboration with Mount Kenya University (MKU), one of the largest private universities in Africa.
A new five-year study of chronic kidney disease in children will draw on University of Florida informatics expertise to investigate how medication and blood pressure monitoring can improve outcomes.
A successful communication skills training program about clinical trials is expanding to cover pediatric cancer. The workshop trains medical oncology fellows to communicate clearly with patients and their families about the benefits of enrolling in a clinical trial.
Dr. Elizabeth “Betsy” Shenkman, Ph.D., has earned the highest honor for a faculty member at the University of Florida: Distinguished Professor. This rare designation denotes the perseverance necessary to reach extraordinary academic achievement and influence.
Yi Guo, Ph.D., is a collaborator on new research that has found an association between taking glucosamine, a popular over-the-counter supplement used for joint pain, and a higher likelihood of progressing from mild cognitive impairment to Alzheimer’s disease.
A mother-daughter story of a painful, misunderstood disease is turning into a teachable moment.
McKnight Brain Institute: The project of Yonghui Wu, Ph.D., and Rui Yin, Ph.D., aims to develop innovative computational tools and analytical frameworks to better understand why some Alzheimer’s patients progress rapidly and others slowly, to improve future clinical trial design and interventions.
